| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5489 | Vuf16216 | Novel CXCR3 ligand, photoswitching from antagonism to agonism |
|
| DCC5490 | Vuf16620 | Novel photoswitchable modulator of the CXCR3 chemokine receptor |
|
| DCC5491 | vuf5228 | Histamine H3 receptor antagonist |
|
| DCC5492 | Vuf5391 | H3R inverse agonist |
|
| DCC5493 | vuf5455 | Adenosine A3 receptor (A3AR) allosteric modulator |
|
| DCC5494 | Vuf5834 | Novel full inverse agonist at CXCR3 N3.35A |
|
| DCC5495 | Vuf-6884 | Full agonist of hH4R with ~300-fold selectivity over hH3R and hH2R, but showing potent inverse agonistic activity at hH1R |
|
| DCC5496 | Vuf-8430 | Potent histamine H4 receptor full agonist |
|
| DCC5497 | Vuf8504 | Allosteric modulator of A3 adenosine receptors |
|
| DCC5498 | Biricodar(Vx-710) Featured | Biricodar (VX-710) is a modulator of P-glycoprotein and MRP-1; shows effective chemosensitizing activity in multidrug resistant cells. |
|
| DCC5499 | Vzmc013 | Novel Probe of Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity |
|
| DCC5500 | w-13 Hydrochloride Featured | W-13 hydrochloride is a calmodulin antagonist. W-13 hydrochloride can inhibit Tamoxifen (HY-13757A)-resistant human breast cancer cell growth. |
|
| DCC5501 | w-5 Hydrochloride | Calmodulin antagonist, inhibiting Ca2+/calmodulin-regulated enzyme activities |
|
| DCC5502 | waladin1 | Mixed competitive/noncompetitive inhibitor of |
|
| DCC5503 | Wallichoside | Nocel inhibitor of BMI1 promoter activity, decreasing BMI1 protein levels in HCT116 human colon carcinoma cells, significantly reducing levels of the CSC biomarker epithelial cell adhesion molecule and diminishing the self-renewal capability of CSCs |
|
| DCC5504 | Way103 | Very late adhesion molecule 4 (VLA-4) antagonist, inhibiting VLA-4/VCAM-1 ligation as a means of modulating eosinophil functions beyond its action on cell adhesion and migration |
|
| DCC5505 | Way-123783 | SGLT2 inhibitor |
|
| DCC5506 | way-133537 | ATP-sensitive potassium channel opener |
|
| DCC5507 | Way-151693 | Inhibitor of human collagenase-3 (MMP-13) |
|
| DCC5508 | Way-170523 | Potent and selective inhibitor of matrix metalloprotease MMP-13 (Collagenase-3) |
|
| DCC5509 | Way-171230 | Inhibitor of matrix metalloproteinase-1 (MMP-1) |
|
| DCC5510 | Way-260022 | Potent and Selective Inhibitor of the Norepinephrine Transporter |
|
| DCC5511 | Way-316606 Hydrochloride | Secreted frizzled-related protein-1 (sFRP-1) modulaitor |
|
| DCC5512 | Wb-308 | Novel inhibitor of The epidermal growth factor receptor (EGFR), decreasing NSCLC cell proliferation and colony formation, by causing G2/M arrest and apoptosis. |
|
| DCC5513 | Wb4-24 | Non-peptide GLP-1 receptor agonist, blocking inflammatory nociception by stimulating β-endorphin release from spinal microglia |
|
| DCC5514 | Wck5153 | Novel Inhibitor of PBP2, Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones |
|
| DCC5515 | We-14 Tfa Salt | Highly conserved neuropeptide derived from Chromogranin A (Parathyroid Secretory Protein 1) |
|
| DCC5516 | Web2347 | Novel very potent and long acting hetrazepinoic PAF-antagonist |
|
| DCC5517 | Wen05-03 | Novel inhibitor of type III secretion system ATPase EscN from enteropathogenic Eecherichia coli |
|
| DCC5518 | Wfq-228 | Novel fluoroquinolone antibiotic with potent antimicrobial activity, showing the potential to overcome major drug resistance; its antimicrobial activity was less affected by both pump-mediated efflux and QRDR mutations in P. aeruginosa compared with LVX a |
|
